• Alnylam Pharmaceuticals EPS for the quarter ending June 30, 2024 was $-0.13, a 94.12% decline year-over-year.
• Alnylam Pharmaceuticals 2023 annual EPS was $-3.52, a 62.15% decline from 2022.
• Alnylam Pharmaceuticals 2022 annual EPS was $-9.3, a 29.17% increase from 2021.
• Alnylam Pharmaceuticals 2021 annual EPS was $-7.2, a 3.49% decline from 2020.

Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.